Clinical Trial Update: Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Elranatamab in high-risk smoldering multiple myeloma. The study is currently recruiting and is sponsored by Stichting E…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smoldering Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)

Snippet

Sponsor: Stichting European Myeloma Network | Conditions: Smoldering Multiple Myeloma | Phase 2 | Status: RECRUITING